

REFERENCES:

1. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood*. 2016;127:2742–2750.
2. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al., editors. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon: International Agency for Research on Cancer; 2008.
3. Schwind S, Edwards CG, Nicolet D, et al. *inv(16)/t(16;16)* acute myeloid leukemia with non-type A CFBF-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. *Blood*. 2013;121:385–391.
4. Merzianu M, Medeiros LJ, Cortes J, et al. *inv(16)(p13q22)* in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. *Am J Clin Pathol*. 2005;124:807–814.
5. Heim S, Christensen BE, Fioretos T, et al. Acute myelomonocytic leukemia with *inv(16)(p13q22)* complicating Philadelphia chromosome positive chronic myeloid leukemia. *Cancer Genet Cytogenet*. 1992;59:35–38.
6. Secker-Walker LM, Morgan GJ, Min T, et al. Inversion of chromosome 16 with the Philadelphia chromosome in acute myelomonocytic leukemia with eosinophilia. Report of two cases. *Cancer Genet Cytogenet*. 1992;58:29–34.
7. Jean McGowan-Jordan, Ros J. Hastings, Sarah Moore (2020): *An International System for Human Cytogenomic Nomenclature*, Basel, Switzerland: S. Karger; 2020.